Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 1

Status

Completed 6Terminated 1

Sponsor Class

INDUSTRY 6OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 3Other solid neoplasm 2Tumor-Agnostic 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Neoplasms 2Mesothelioma 2Triple Negative Breast Neoplasms 1Thymoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Medical Oncology 1Lung Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 489Carboplatin 435Gemcitabine 394Docetaxel 385Cisplatin 359pembrolizumab 343Bevacizumab 335Nivolumab 261Pemetrexed 242Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 91

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Completed × INDUSTRY × anetumab ravtansine × Clear all
NCT03102320 2022-06-30

ARCS-Multi

Bayer

Phase 1 Completed
173 enrolled
BreastGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Pancreatic Neoplasms, Thymoma, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT02696642 2021-07-09

Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment

Bayer

Phase 1 Completed
54 enrolled
Tumor-Agnostic

Neoplasms

NCT02610140 2020-11-04

Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)

Bayer

Phase 2 Completed
248 enrolled 23 charts
Other solid neoplasmThoracic

Mesothelioma

NCT02824042 2020-07-31

Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole

Bayer

Phase 1 Completed
63 enrolled

Medical Oncology

NCT02751918 2019-11-22

Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer

Bayer

Phase 1 Completed
65 enrolled
Gynecologic

Ovarian Neoplasms

NCT02639091 2019-11-07

Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors

Bayer

Phase 1 Completed
36 enrolled
Other solid neoplasmThoracic

Lung Neoplasms, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡